Content » Preview

Clinical Report

Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU)

Athanasios Tsianakas, Claudia Zeidler, Claudia Riepe, Matthias Borowski, Caroline Forner, Joachim Gerss, Martin Metz, Petra Staubach, Ulrike Raap, Martin Kaatz, Marc Urban, Thomas A. Luger, Sonja Ständer
DOI: 10.2340/00015555-3120

Preview of fully accepted paper, still not published in any volume

Abstract

The aim of this multicentre, randomized, double-blind, placebo-controlled, cross-over, phase-II study was to determine the antipruritic effect of aprepitant vs. placebo in 58 patients with anti-histamine-refractory chronic pruritus in chronic nodular prurigo. Patients were randomized to receive either first oral aprepitant 80 mg/day or placebo for 4 weeks. Following a 2-week wash-out phase, the patients were crossed-over to receive the other treatment for 4 weeks. Primary efficacy criterion was the intra-individual difference between mean itch intensity (visual analogue scale) at baseline compared with the end of treatment period. Prurigo lesions, pruritus course, quality of life, patient benefits, and safety were secondary parameters. No significant differences were found between aprepitant treatment and placebo for any of the parameters investigated. Under the experimental conditions of the study, aprepitant, 80 mg daily for 4 weeks, did not have an antipruritic effect in patients with chronic prurigo. (DRKS00005594; EudraCT Number: 2013-001601-85).

Supplementary content

Comments

Not logged in! You need to login/create an account to comment on articles. Click here to login/create an account.